CTOs on the Move


 
Biomerieux is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Coley Pharmaceutical Group

Coley Pharmaceutical Group is a Wellesley Hills, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acrometrix

Acrometrix is a Benicia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

K Biosciences

K Biosciences is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prime Medicine

Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.

Vestaron

Recent winner of the Green Chemistry award, Vestaron is leading a peptide-based revolution in crop protection. We are committed to providing growers with novel, effective chemistries that address proven targets. Our peptides overcome existing resistance issues while offering a desired safety profile for workers, beneficials and the environment. Initially, Vestaron is focused on a class of peptides that kills insect pests efficiently, but is safe for humans, birds, fish, pollinators and the environment. As part of this, the company has developed a proprietary platform for peptide optimization and fermentation-based peptide production that will allow development of a wide variety of biologic crop protection solutions. Vestaron is proud to bring you the Power of Peptides through the SPEAR® brand family - providing new technology with a unique mode of action in a biological solution equal to, and often better, than the synthetic options; creating the opportunity to incorporate a new IRAC Group 32 into rotation recommendations for resistance management.